News

CMN Weekly (11 November 2022) - Your Weekly CRISPR Medicine News

Some of the best links we picked up around the internet

By: Gorm Palmgren - Nov. 11, 2022

Top picks

  • The primary patient of an N-of-1 clinical CRISPR trial tragically died less than two months after FDA approved the trial. However, no official statement has currently linked the trial and the death. The trial, CRD-TMH-001, was carried out by the non-profit organization Cure Rare Disease, and the diseased patient was the brother of the organization's founder, Rich Horgan. The trial intended to upregulate an alternate form of the dystrophin protein using CRISPR technology, thereby stabilizing or potentially reversing symptom progression of Duchenne muscular dystrophy (DMD).
  • Two papers - published back-to-back in Science - report on RNA-triggered protein cleavage by the type III-E CRISPR-Cas7-11 nuclease-protease. The achievements were independently published by Feng Zhang's lab and Japanese researchers. Target RNA binding of the Cas7-11–crRNA–Csx29 complex induces conformational changes in the Csx29 protease. The complex could be engineered for programmable RNA-activated endopeptidase activity and RNA sensing in mammalian cells.

Research

Industry

Detection

Reviews

Opinions

Financial reports

To get more of the CRISPR Medicine News delivered to your inbox, sign up to the free weekly CMN Newsletter here.

Tags

HashtagArticleHashtagMissing linksHashtagNewsHashtagCMN Weekly

News: CMN Weekly (11 November 2022) - Your Weekly CRISPR Medicine News
Search your next CRISPR job here...
Search your next CRISPR job here...
CLINICAL TRIALS
Solid Tumors (NCT03970382)
Sponsors:
PACT Pharma, Inc.
Indicator
IND Enabling
Phase I
Phase II
Phase III
Beta-Thalassemia, BT, (NCT05442346)
Sponsors:
Bioray Laboratories
IND Enabling
Phase I
Phase II
Phase III
IND Enabling
Phase I
Phase II
Phase III
View all clinical trials
close
Search CRISPR Medicine